12 recruiting, 7 completed, 4 unknown, 3 active not recruiting. 29 Phase 1, 9 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 29 | Recruiting 12, Completed 7, Unknown 4, Active not recruiting 3, Terminated 2, Not yet recruiting 1 |
| Phase 2 | 9 | Recruiting 6, Unknown 2, Active not recruiting 1 |
Follow Tumor, Solid: new trials by email Literature Review of Tumor, Solid trials Research Report on Tumor, Solid
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of RGL-270 Single Drug and Combined With Adebelimab in Patients in Patients at High Risk of Recurrence After Radical Treatment of Malignant Solid Tumors RGL-270 Injection, Adebelimab Injection - Tumor, Solid | Phase 1 | Recruiting | Xian-Jun Yu | 198 | 2025-09-07 | 2026-01-16 |
| NW-301 TCR-T in Patients With Advanced Solid Tumor NW-301V, Drug: NW-301D - Tumor, Solid | Phase 1 | Not yet recruiting | Peking University | 44 | 2025-05-10 | 2025-05-04 |
| A Study of PARG Inhibitor XNW29016 in Patients With Advanced Solid Tumors Who Failed Standard Treatment XNW29016 - Tumor, Solid | Phase 1 / Phase 2 | Recruiting | Evopoint Biosciences Inc. | 132 | 2025-04-11 | 2026-10-16 |
| AD1208 in Subjects With Any Progressive, Locally Advanced or Metastatic Solid Tumors AD1208 - Solid Tumor, Adult, Tumor, Solid | Phase 1 / Phase 2 | Recruiting | Avelos Therapeutics Inc. | 36 | 2025-03-11 | 2025-04-04 |
| Carbon Nanoparticle-Loaded Iron in the Treatment of Advanced Solid Tumor Carbon Nanoparticle-Loaded Iron [CNSI-Fe], Carbon Nanoparticle-Loaded Iron - Tumor, Solid, Lung Cancer | Phase 1 / Phase 2 | Recruiting | Sichuan Enray Pharmaceutical Sciences Company | 54 | 2024-11-12 | 2026-02-25 |
| TumorGlow Intraoperative Molecular Imaging (IMI) Indocyanine Green - Tumor, Solid | Phase 1 / Phase 2 | Recruiting | University of Pennsylvania | 500 | 2024-08-14 | 2026-03-09 |
| T Cell Receptor Gene-Engineered T Cell Therapy Targeting KRAS Mutations in the Treatment of Subjects With Advanced Solid Tumor NW-301V, NW-301D - Tumor, Solid | Phase 1 | Recruiting | Tao Zhang | 9 | 2024-06-19 | 2025-07-31 |
| T Cell Receptor Gene-Engineered T Cell Therapy Targeting KRAS Mutations in the Treatment of Subjects With Advanced Solid Tumor NW-301V, NW-301D - Tumor, Solid | Phase 1 | Recruiting | Ting Deng | 9 | 2024-04-08 | 2025-11-25 |
| T Cell Receptor Gene-Engineered T Cell Therapy Targeting KRAS Mutations in the Treatment of Subjects With Advanced Solid Tumor NW-301V, NW-301D - Tumor, Solid | Phase 1 | Active not recruiting | TingBo Liang | 18 | 2024-02-01 | 2026-10-15 |
| LEU01101: Safety and Preliminary Efficacy of LEU011 in Solid Tumours. LEU011 - Tumor, Solid | Phase 1 / Phase 2 | Recruiting | Leucid Bio | 17 | 2023-11-13 | 2026-08-31 |
| A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents OR502, Cemiplimab - Cancer, Tumor, Solid | Phase 1 / Phase 2 | Recruiting | OncoResponse, Inc. | 168 | 2023-10-24 | 2025-01-07 |
| A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas. ONM-501, Cemiplimab - Triple Negative Breast Cancer, Diffuse Large B Cell Lymphoma | Phase 1 | Recruiting | OncoNano Medicine, Inc. | 168 | 2023-10-13 | 2025-12-24 |
| Dose-escalation Study to Assess Safety and Pharmacokinetics of Nab-Sirolimus in Patients With Locally Advanced or Metastatic Solid Tumors and Moderate Liver Impairment nab-sirolimus - Tumor, Solid, Tumor | Phase 1 | Completed | Aadi Bioscience, Inc. | 15 | 2022-11-23 | 2026-10-28 |
| Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer JK08, Pembrolizumab, Lenvatinib Pill - Cancer, Tumor, Solid | Phase 1 / Phase 2 | Active not recruiting | Salubris Biotherapeutics Inc | 263 | 2022-10-17 | 2024-10-15 |
| A Study of NTX-1088, a Monoclonal Antibody Targeting the Poliovirus Receptor (PVR, CD155), as Monotherapy and Combined With Pembrolizumab NTX-1088, Pembrolizumab - Cancer, Tumor, Solid | Phase 1 | Active not recruiting | Nectin Therapeutics Ltd | 90 | 2022-09-01 | 2026-04-30 |
| A Study of HMBD-002, a Monoclonal Antibody Targeting VISTA, as Monotherapy and Combined With Pembrolizumab, in Patients With Advanced Solid Tumors HMBD-002, Pembrolizumab - Cancer, Tumor, Solid | Phase 1 | Completed | Hummingbird Bioscience | 48 | 2022-02-28 | 2025-10-16 |
| A Study Investigating agenT-797 in Participants With Relapsed/Refractory Solid Tumors agenT-797, Approved ICIs - Tumor, Solid | Phase 1 | Completed | MiNK Therapeutics | 34 | 2022-01-28 | 2024-04-24 |
| A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents OR2805, Cemiplimab, Docetaxel - Cancer, Tumor, Solid | Phase 1 / Phase 2 | Unknown | OncoResponse, Inc. | 172 | 2021-09-09 | 2023-11-02 |
| Clinical Study of BDB018: Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors BDB018, Pembrolizumab - Tumor, Solid | Phase 1 | Completed | Eikon Therapeutics | 1 | 2021-06-22 | 2025-11-12 |
| Study of TBX-3400 in Subjects With Solid Malignant Tumors Resistant or Refractory to Standard Therapies TBX-3400 - Cancer, Tumor, Solid | Phase 1 / Phase 2 | Unknown | Taiga Biotechnologies, Inc. | 60 | 2021-01-25 | 2022-02-02 |
Showing 20 of 29. Sign in to see all of them.
Neoplasms (29) · Neoplasm Metastasis (8) · Melanoma (5) · Carcinoma, Non-Small-Cell Lung (4) · Colorectal Neoplasms (3) · Pancreatic Neoplasms (3) · Squamous Cell Carcinoma of Head and Neck (3) · Triple Negative Breast Neoplasms (3) · Uterine Cervical Neoplasms (3) · Lymphoma (2) · Thyroid Neoplasms (2) · Bites and Stings (1) · Breast Neoplasms (1) · Carcinoma (1) · Carcinoma in Situ (1)
Neoplasms by Site (8) · Neoplastic Processes (8) · Pathologic Processes (8) · Pathological Conditions, Signs and Symptoms (8) · Neoplasms by Histologic Type (7) · Skin Diseases (6) · Skin and Connective Tissue Diseases (6) · Lung Diseases (5) · Neoplasms, Germ Cell and Embryonal (5) · Neoplasms, Nerve Tissue (5) · Neuroectodermal Tumors (5) · Neuroendocrine Tumors (5) · Nevi and Melanomas (5) · Respiratory Tract Diseases (5) · Respiratory Tract Neoplasms (5)
pembrolizumab (6) · cemiplimab (3) · BDB001 (2) · Docetaxel (1) · Indocyanine Green (1) · Injections (1) · MK-8353 (1) · atezolizumab (1) · lenvatinib (1) · palbociclib (1) · ulixertinib (1)
Eikon Therapeutics (3) · OncoResponse, Inc. (2) · Aadi Bioscience, Inc. (1) · Andes Biotechnologies (1) · Avelos Therapeutics Inc. (1) · Chinese Academy of Medical Sciences (1) · Evopoint Biosciences Inc. (1) · Hummingbird Bioscience (1) · Jiangsu HengRui Medicine Co., Ltd. (1) · Leucid Bio (1) · Merck Sharp & Dohme LLC (1) · MiNK Therapeutics (1) · Navire Pharma Inc., a BridgeBio company (1) · Nectin Therapeutics Ltd (1) · OncoNano Medicine, Inc. (1)
United States (15) · China (9) · Israel (2) · Australia (1) · Belgium (1) · Chile (1) · Poland (1) · South Korea (1) · Spain (1) · United Kingdom (1)
Harry Raftopoulos, MD (3) · Bernadita Mendez, PhD (1) · John Maher (1) · Stergios Moschos, MD (1) · Ying Cheng, Prof. (1)